产品
编 号：F757999
分子式：C164H255N47O37S
分子量：3509.13
分子式：C164H255N47O37S
分子量：3509.13
产品类型
规格
价格
是否有货
结构图
CAS No: 392661-17-5
产品详情
生物活性：
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research.
体内研究：
PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo.PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor .Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)
Dosage:2 mg/mouse
Administration:Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr
Result:No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor.
Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)
Dosage:1 mg/mouse, 10 mg/mouse and 20 mg/mouse
Administration:When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days
Result:Resulted in a significant level of tumor growth inhibition in a dose-related manner.
体外研究：
PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line.
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research.
体内研究：
PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo.PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor .Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)
Dosage:2 mg/mouse
Administration:Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr
Result:No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor.
Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)
Dosage:1 mg/mouse, 10 mg/mouse and 20 mg/mouse
Administration:When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days
Result:Resulted in a significant level of tumor growth inhibition in a dose-related manner.
体外研究：
PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备